3,4-Dimethylmethcathinone

3,4-Dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone, following its widespread abuse in many countries in Europe and around the world.^[1] 3,4-DMMC has been seized as a designer drug in Australia.^[2] In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake, and to a lesser extent dopamine reuptake.^[3]

3,4-Dimethylmethcathinone

Clinical data
ATC code	none
Legal status
Legal status	DE: Anlage II (Authorized trade only, not prescriptible) UK: Class B US: Schedule I
Identifiers
IUPAC name (±)-1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one
CAS Number	1082110-00-6 N
PubChem CID	52988261
ChemSpider	25630192 Y
UNII	C4EW58DTW5
CompTox Dashboard (EPA)	DTXSID501016968
Chemical and physical data
Formula	C12H17NO
Molar mass	191.274 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1ccc(C(=O)C(C)NC)cc1C
InChI InChI=1S/C12H17NO/c1-8-5-6-11(7-9(8)2)12(14)10(3)13-4/h5-7,10,13H,1-4H3 Y Key:IBZRXTVDTGVBIS-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Legal Status

As of October 2015 3,4-DMMC is a controlled substance in China.^[4]

3,4-DMMC is banned in the Czech Republic.^[5]

In the United States 3,4-DMMC is considered a Schedule I controlled substance as a positional isomer of 4-Methylethcathinone (4-MEC).^[6]

See also

• Serotonin–norepinephrine–dopamine reuptake inhibitor
• Serotonin–norepinephrine reuptake inhibitor
• Substituted cathinone
• Indanylaminopropane
• Methylone
• Xylopropamine